Current Psychiatry Reports

, Volume 13, Issue 4, pp 243–244

What Can We Expect From Long-Acting Formulations for Schizophrenia?

CLINICAL TRIAL REPORT

DOI: 10.1007/s11920-011-0206-2

Cite this article as:
Siegel, S.J. Curr Psychiatry Rep (2011) 13: 243. doi:10.1007/s11920-011-0206-2

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of Translational Neuroscience, Department of PsychiatryUniversity of PennsylvaniaPhiladelphiaUSA